Applied Molecular Transport Inc. (AMTI): Price and Financial Metrics
AMTI Price/Volume Stats
Current price | $0.20 | 52-week high | $1.39 |
Prev. close | $0.21 | 52-week low | $0.18 |
Day low | $0.20 | Volume | 23,979,000 |
Day high | $0.28 | Avg. volume | 482,462 |
50-day MA | $0.27 | Dividend yield | N/A |
200-day MA | $0.42 | Market Cap | 8.04M |
AMTI Stock Price Chart Interactive Chart >
Applied Molecular Transport Inc. (AMTI) Company Bio
Applied Molecular Transport, Inc. is a clinical-stage biopharmaceutical company, which engages in the design and development of a pipeline of novel oral biologic product candidates for the treatment of autoimmune, inflammatory, and metabolic diseases. The company was founded by Tahir Mahmood and Randall J. Mrsny on November 21, 2016 and is headquartered in South San Francisco, CA.
Latest AMTI News From Around the Web
Below are the latest news stories about APPLIED MOLECULAR TRANSPORT INC that investors may wish to consider to help them evaluate AMTI as an investment opportunity.
Applied Molecular Transport Reports Second Quarter 2023 Financial ResultsCurrently Pursuing Strategic Alternatives, with MTS Health Partners, L.P. Advising the Company Cash and Cash Equivalents of $22.5 million, as of June 30, 2023 SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2023. Financial Results for the Second Quarter Ended June 30, 2023 Research and development (R&D) expenses. Total R&D expen |
Positive Signs As Multiple Insiders Buy Applied Molecular Transport Stock \When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase... |
Applied Molecular Transport Reports First Quarter 2023 Financial ResultsSOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2023. Recent Business Highlights Engaged MTS Health Partners, L.P. as advisors in a process to explore strategic alternatives for the companyAppointed Shawn Cross to serve as chief executive officer and board chairTahir Mahmood, Ph.D., co-founder and former CEO remains a member of t |
Applied Molecular Transport Announces Corporate Leadership Change and Process to Explore Strategic AlternativesSOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company’s board of directors approved a workforce reduction of approximately 57% of its employee base and the engagement of MTS Health Partners, L.P. as advisors in a process to explore strategic alternatives for the company. As part of the restructuring, Tahir Mahmood, Ph.D., will leave his post as chief execu |
What Makes Applied Molecular Transport Inc. (AMTI) a New Buy StockApplied Molecular Transport Inc. (AMTI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
AMTI Price Returns
1-mo | -31.03% |
3-mo | -23.08% |
6-mo | -49.19% |
1-year | -82.61% |
3-year | -99.33% |
5-year | N/A |
YTD | -52.38% |
2022 | -97.00% |
2021 | -54.57% |
2020 | N/A |
2019 | N/A |
2018 | N/A |
Loading social stream, please wait...